News Releases

Filter by:

Showing 12 of 537 Results

June 1, 2023 General

Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 8, 2023 Earnings

Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview

May 5, 2023 General

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2023 General

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

April 25, 2023 General

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023

April 20, 2023 General

Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting

April 17, 2023 General

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome

April 11, 2023 General

Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

March 10, 2023 General

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

February 27, 2023 Earnings

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview

February 14, 2023 General

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

February 13, 2023 General

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Load More Results